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Maternal Allopurinol During Fetal Hypoxia Lowers
Cord Blood Levels of the Brain Injury Marker S-100B
WHAT’S KNOWN ON THIS SUBJECT: Moderate hypothermia
showed some protection in selected groups of asphyxiated
newborns. Combining hypothermia with postnatal pharmacologic
treatment may further reduce post–hypoxic-ischemic reperfusion
injury. Postnatal pharmacologic treatment, however, has not yet led to a
signiﬁcant improvement.
WHAT THIS STUDY ADDS: This is the ﬁrst clinical study to
investigate whether maternal treatment of the hypoxic fetus may
lead to a reduction of the devastating consequences of birth
asphyxia.
abstract
BACKGROUND: Fetal hypoxia is an important determinant of neonatal
encephalopathy caused by birth asphyxia, in which hypoxia-induced
free radical formation plays an important role.
HYPOTHESIS: Maternal treatment with allopurinol, will cross the pla-
centa during fetal hypoxia (primary outcome) and reduce S-100B and
free radical formation (secondary outcome).
METHODS: In a randomized, double-blind feasibility study, 53 pregnant
women in labor (54 fetuses) with a gestational age of36 weeks and
fetal hypoxia, as indicated by abnormal/nonreassuring fetal heart rate
tracing or fetal scalp pH of 7.20, received 500 mg of allopurinol or
placebo intravenously. Severity of fetal hypoxia, brain damage and free
radical formation were assessed by arterial cord blood lactate, S-100B
and non-protein-bound-iron concentrations, respectively. At birth, ma-
ternal and cord blood concentrations of allopurinol and its active me-
tabolite oxypurinol were determined.
RESULTS: Allopurinol and oxypurinol concentrations were within the
therapeutic range in the mother (allopurinol 2 mg/L and/or oxypuri-
nol  4 mg/L) but not always in arterial cord blood. We therefore
created 3 groups: a placebo (n 27), therapeutic allopurinol (n 15),
and subtherapeutic allopurinol group (n  12). Cord lactate concen-
tration did not differ, but S-100B was signiﬁcantly lower in the thera-
peutic allopurinol group compared with the placebo and subtherapeu-
tic allopurinol groups (P  .01). Fewer therapeutic allopurinol cord
samples had measurable non–protein-bound iron concentrations
compared with placebo (P .01).
CONCLUSIONS: Maternal allopurinol/oxypurinol crosses the placenta
during fetal hypoxia. In fetuses/newbornswith therapeutic allopurinol/
oxypurinol concentrations in cord blood, lower plasma levels of the
brain injury marker protein S-100B were detected. A larger allopurinol
trial in compromised fetuses at term seemswarranted. The allopurinol
dosage must be adjusted to achieve therapeutic fetal allopurinol/
oxypurinol concentrations. Pediatrics 2009;124:350–357
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A more speciﬁc approach to improve
neurodevelopmental outcome after
perinatal hypoxia-ischemia or birth as-
phyxia is an important issue nowa-
days. Moderate hypothermia of the
brain or the whole body has been
proven to reduce brain damage after
moderate-to-severe birth asphyxia.1–4
However, it is conceivable that combin-
ing this technique with a pharmaco-
logic means of neuroprotection after
birth asphyxia will further improve
neurodevelopmental outcome.5 Ex-
perimental and clinical studies point
to several compounds that may be
good candidates for this purpose.6–9
However, a major drawback in post-
asphyxial hypothermia or pharmaco-
logic treatment is the small thera-
peutic window (at best within 6 hours
after birth) in which treatment should
be initiated.5,10 This window is even
smaller when one aims to prevent or
reduce free radical stress, an im-
portant cause of early reperfusion/
reoxygenation injury to the immature
brain. Free radical formation occurs
on reperfusion and reoxygenation with
its maximal formation within the ﬁrst
30 minutes after birth.11,12 The opti-
mal point in time to start antioxidative
treatment is at birth or even before
birth. Because fetal hypoxia is an im-
portant determinant in the etiology of
birth asphyxia-related encephalopa-
thy, maternal treatment with antioxi-
dative drugs, whether combined with
early postnatal treatment such as hy-
pothermia, may be a more optimal ap-
proach for reduction of reperfusion-
reoxygenation injury after perinatal
hypoxia-ischemia.
In the present feasibility study, we in-
vestigated whether allopurinol, a xan-
thine oxidase inhibitor, and in higher
concentrations also a direct scaven-
ger of the toxic hydroxyl free radical
and a chelator of non–protein-bound
iron (NPBI),13–15 reduced free radical
formation in the fetus. There were sev-
eral reasons for choosing allopurinol:
the increasing evidence that allopuri-
nol and its active metabolite oxy-
purinol improve neurodevelopmental
outcome after moderate-to-severe
perinatal hypoxia-ischemia when used
in the early neonatal period9,16,17; its
proven ability to cross the human
placenta18; and its proven safety
proﬁle.9,13,16,18,19
Therefore, we treated pregnant
women with signs of fetal hypoxia, on
the brink of delivery, in a double-blind,
randomized manner, with intrave-
nously administered allopurinol or a
placebo. We hypothesized that mater-
nally administered allopurinol crosses
the placenta during fetal hypoxia
(primary outcome), reduces fetal free
radical formation, and ameliorates
hypoxia-ischemia–related brain dam-
age on the short-term as indicated by a
decrease in fetal S-100B (secondary
outcomes).
PATIENTS AND METHODS
Women in labor (gestational age of
36 weeks) with signs of fetal dis-
tress (as indicated by abnormal or
nonreassuring fetal heart rate tracing
as deﬁned by the FIGO (International
Federation of Gynecology and Obstet-
rics) criteria20 or fetal scalp pH of
7.2021) were treated in a double-
blind, randomized manner with either
a single intravenous dose of 500 mg of
allopurinol or a placebo (saline). Ran-
domization was performed by the De-
partment of Pharmacy of the Univer-
sity Medical Center Utrecht. Rando-
mization sequence was generated by a
computer program (Design 2.0 [Systat,
Inc, Evanston, IL]) in blocks of 4. Pa-
tients were therefore randomly as-
signed to treatment with allopurinol or
placebo according to this randomiza-
tion sequence. Study drugs were pre-
pared and labeled in a blind manner.
Every site was supplied with study
drug packages that were labeled with
a unique set of numbers. The study
drugs were stored at 20°C and
thawed on the ward immediately be-
fore administration. Study medication
was administered intravenously over
10 minutes after a thorough explana-
tion and written consent from the
mother and father, while the mother
was being prepared for an emergency
cesarean section or assisted vaginal
delivery. In addition, women received
acute tocolysis (either ritodrine or
atosiban) to abolish additional detri-
mental effects of contractions on the
fetal condition. The dose of allopurinol
was derived from a study performed in
healthy women in labor without fetal
distress.18 Women with signs of severe
fetal distress who were being pre-
pared for an emergency cesarean
section were excluded from the study
because of lack of time to properly pre-
pare and perform the study protocol.
Maternal blood samples were ob-
tained at the time of birth. Fetal blood
samples were obtained from arterial
cord blood. Maternal and cord blood
investigation included plasma concen-
trations of allopurinol and oxypurinol
and plasma concentrations of the free
radical markers isoprostanes, total
hydroperoxide, thiol groups, and NPBI.
In addition, to assess the severity of
fetal hypoxia, arterial cord lactate con-
centration was measured.22 Protein
S-100B concentration in arterial cord
blood was used as a marker of
central nervous system damage.23–25
In addition, arterial cord plasma con-
centrations of liver functions (alanine
aminotransferase, aspartate amino-
transferase), renal function (urea, cre-
atinine), uric acid, and troponin 1
(myocardial function marker) were
determined. Blood samples for allo-
purinol and oxypurinol determination
were collected in heparinized tubes,
centrifuged, and stored at20°C until
analysis. Blood samples for evaluation
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of oxidative stress were centrifuged at
2000 rpm for 10 minutes, and the su-
pernatant was stored with butylated
hydroxytoluene, to prevent continua-
tion of the oxidation process, at a tem-
perature of80°C.
All of the neonates participating in the
study were examined medically after
birth. Adverse effects of allopurinol on
the white blood cell count and on the
skin were monitored in the mothers
and children.13,26
The study was approved by the scien-
tiﬁc boards and ethical committees of
the participating hospitals (University
Medical Center Utrecht, University
Medical Center Groningen, and Univer-
sidad Del Norte, Barranquilla). Recruit-
ment took place in 2006 and 2007.
Analysis of Allopurinol, Oxypurinol,
Total Hydroperoxide, Thiol Groups,
Isoprostanes, and NPBI
The allopurinol and oxypurinol plas-
ma concentrations were deter-
mined by using reversed-phase, high-
performance liquid chromatography
with UV-detection at 254 nm for the
quantiﬁcation of allopurinol and oxy-
purinol in plasma.27 The method was
linear between 0.5 and 25 mg/L with a
lower limit of quantiﬁcation of 0.2mg/L
for both compounds. F2-isoprostanes
in plasma were measured by using the
method of Morrow,28 by selected ion
monitoring gas chromatography/
negative ion chemical ionization-mass
spectrometry employing [2H4] 8-
iso-prostaglandin F2a as an internal
standard. Total hydroperoxide pro-
duction was measured with a d-ROMs
test (Diacron International, Grosseto,
Italy). Thiol production was measured
with a SHp test (Diacron International),
which is based on the ability of thiol
groups to develop a photometrically
detectable colored complex. The inten-
sity of photometrically detected color
is directly proportional to the concen-
tration of thiols. Finally, detection of
NPBI in plasma is based on preferen-
tial chelation of NPBI by a large excess
of nitrilotriacetic acid, low afﬁnity li-
gand (NTA). NTA captures all iron
bound to low molecular weight pro-
teins and nonspeciﬁcally bound to se-
rum proteins; however, it does not re-
move iron bound to transferrin or
ferritin.29
Statistical Analysis
Data are summarized as means  SD
or as median and ranges (shown as
box-whisker plots [representing
means, quartiles, and outliers]) where
appropriate. Differences between the
2 groups were compared by the (un-
paired) Student’s t test, Mann-Whitney
U test, or 2 test where appropriate.
Differences between groups were as-
sessed with one-factorial analysis of
variance followed by the Scheffe pro-
cedure if a signiﬁcant difference was
found. A possible correlation was in-
vestigated with simple regression
analysis. For statistical analysis, STAT
VIEW II (Abacus Concepts, Inc, Berkeley,
CA) was used. Statistical signiﬁcance
was set at P .05.
RESULTS
Initially, 112 women were assessed for
eligibility; 21 women refused to partic-
ipate, 13 did not meet the inclusion cri-
teria, and 25 were excluded for other
reasons (such as insufﬁcient time to
properly prepare and perform the
study protocol). A total of 53 mothers
and 54 infants were included in the
present study (Utrecht, n  38; Gro-
ningen, n  4; Barranquilla, n  11):
27 placebo-treated mothers and 26 al-
lopurinol-treated mothers (1 multiple
gestation). The allopurinol group was
subdivided into a therapeutic allopuri-
nol and/or oxypurinol (n  15) and a
subtherapeutic allopurinol and/or oxy-
purinol (n 12) group on the basis of
cord concentrations of allopurinol
and/or oxypurinol (see also below). Ta-
ble 1 gives relevant maternal charac-
teristics as a function of treatment. No
differences were found for any of the
parameters shown.
Table 2 provides relevant perinatal
data of the neonates as a function of
treatment. Gestational age, birth
weight, Apgar score, arterial umbilical
cord pH, and base excess did not differ
between allopurinol- and placebo-
treated newborns. Seventeen placebo,
6 subtherapeutic allopurinol and/or
oxypurinol, and 5 therapeutic allopuri-
nol and/or oxypurinol newborns had to
be admitted to the neonatal ward; this
was related to preceding fetal hypoxia
in 8, 4, and 4 newborns, respectively.
Duration of admittance ranged from 3
to 16 days for placebo-treated infants
(median stay: 7 days) and from 1 to 20
days for allopurinol-treated infants
(median stay: 8 days).
Table 3 summarizes chemical markers
with respect to importantorgansystems
such as the liver, renal function, and
heart. No differences were detected be-
tween allopurinol- and placebo-treated
groups. Troponinwasnot elevated in any
of the therapeutic allopurinol and/or
oxypurinol infants compared with 2 and
4 infants in the subtherapeutic allo-
purinol and/or oxypurinol and placebo
groups, respectively.
Maternal and Arterial Cord
Allopurinol and Oxypurinol
Concentrations at Birth
The time from the start of maternal ad-
ministration of allopurinol or placebo
to birth ranged from 18 to 190 minutes
(median: 56 minutes) and 12 to 372
minutes (median: 48 minutes), respec-
tively. Maternal allopurinol and oxy-
purinol concentrations were signiﬁ-
cantly higher compared with arterial
cord concentrations. Figure 1 shows
the box-whisker plots of maternal and
arterial cord concentrations. Maternal
allopurinol and oxypurinol concentra-
tions ranged between 1.2 and 7.9
g/mL (median: 3.8 g/mL) and be-
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tween 1.5 and 6.4 g/mL (median: 3.2
g/mL), respectively. The arterial cord
allopurinol and oxypurinol concentra-
tions ranged between 0.2 and 7.3
g/mL (median: 2.0 g/mL) and 0.6
and 7.6 g/mL (median: 1.5 g/mL),
respectively. Both allopurinol and oxy-
purinol inhibit xanthine oxidase ac-
tivity. On the basis of earlier (phar-
macologic) studies, we considered
allopurinol cord concentrations of
2.0 g/mL and oxypurinol concen-
trations of 4.0 g/mL to be in the
therapeutic range in terms of xanthine
oxidase inhibition.30–32 This was the
case in 15 of the allopurinol-treated
newborns. The 12 remaining allopuri-
nol-treated newborns had subthera-
peutic levels. Oxypurinol, but not allo-
purinol, concentration in cord blood
showed a positive correlation with
time after maternal allopurinol admin-
istration (r 0.71; P .001).
Arterial Cord Lactate and S-100B
Concentrations
Plasma lactate did not differ between
groups. Figure 2 shows the box-
whisker plots for plasma lactate.
Plasma S-100B concentrations, how-
ever, were signiﬁcantly lower in the
therapeutic allopurinol and/or oxy-
purinol group, suggesting less brain
damage compared with the placebo
group. Figure 3A shows the box-
whisker plots for the respective
groups. Moreover, Figure 3B shows a
signiﬁcant correlation between the
sum of allopurinol and oxypurinol con-
centrations on the one hand and
S-100B on the other hand (r  0.59;
P .001).
Free Radical Markers in Maternal
and Arterial Cord Plasma
Maternal free radical markers were
always lower compared with arterial
umbilical samples, except for total hy-
droperoxide concentrations. No signif-
icant differences were detected be-
tween the 3 groups with regard to
isoprostane, thiol groups, total hy-
FIGURE 1
Maternal allopurinol (Mat ALLO) and oxypurinol
(Mat Oxy), and arterial cord allopurinol (Cord
ALLO) and oxypurinol (Cord Oxy) concentrations
at birth shown as box-whisker plots.
FIGURE 2
Arterial cord concentrations of lactate of the
placebo-treated (placebo), therapeutic allo-
purinol and/or oxypurinol (ALLO/OXY), and
subtherapeutic allopurinol and/or oxypurinol
(ALLO/OXY) groups shown as box-whisker
plots.
TABLE 1 Maternal Characteristics as a Function of Treatment Group






Nulliparity, n 7 6 13
Maternal age, median (range), y 30 (26–33) 30 (22–43) 33.5 (24–42)
Multiple gestation, n 1 0 0
Time between infusion and delivery,
median (range), min
56 (24–190) 48 (18–94) 41 (12–449)
Instrumented vaginal delivery, n 2 3 8
Spontaneous vaginal delivery, n 5 0 11
Cesarean delivery, n 7 9 8
TABLE 2 Perinatal and Neonatal Data as a Function of Treatment Group






Gestational age, wk 40 1 40 1 40 1
Birth weight, g 3148 351 3194 740 3189 584
Male gender, n 8 8 15
Apgar score at 5 min 8.7 1.3 9.3 0.6 9.1 0.8
Umbilical artery pH 7.17 0.06 7.15 0.02 7.14 0.10
Umbilical artery BE 10.3 3.3 8.3 3.1 8.9 4.3
Values shown are mean SD or n. BE indicates base excess.
TABLE 3 Important Chemical Markers From the Arterial Cord Blood for Neonatal Liver, Kidney,
Heart, and Brain as a Function of Treatment Group






AST, U/L 43 (28–191) 40 (28–101) 44 (26–100)
ALT, U/L 16 (7–21) 19 (17–26) 17 (7–42)
LD, U/L 934 (541–5668) 1198 (439–4167) 1145 (352–1569)
Creatinine, mol/L 73 (51–126) 68 (60–83) 67 (42–106)
Urea, mmol/L 3.4 (2.7–6.7) 3.4 (1.4–4.5) 3.4 (1.8–7.3)
Uric acid, mmol/L 0.36 (0.22–0.57) 0.30 (0.18–0.38) 0.32 (0.20–0.49)
Troponin, g/L 0 (0–0) 0 (0–0.12) 0 (0–0.28)
Values shown are median (range). AST indicates aspartate aminotransferase; ALT, alanine aminotransferase; LD, lactate
dehydrogenase.
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droperoxide, or NPBI, although the lat-
ter 3markers tended to be lower in the
therapeutic allopurinol and/or oxy-
purinol group compared with the pla-
cebo group. Furthermore, NPBI was
found signiﬁcantly more in placebo
and subtherapeutic allopurinol and/or
oxypurinol cord blood compared with
therapeutic allopurinol and/or oxy-
purinol cord blood (18 of 20 [placebo
group], 10 of 10 [subtherapeutic allo-
purinol and/or oxypurinol group], and
7 of 15 [therapeutic allopurinol and/or
oxypurinol group]; P .05). Seven pla-
cebo and 2 subtherapeutic allopurinol
and/or oxypurinol cord samples were
hemolytic and NPBI could therefore not
be determined reliably. Figure 4 shows
the box-whisker plots of the free radi-
cal markers.
DISCUSSION
To our knowledge, this pilot study is
the ﬁrst to show that allopurinol ad-
ministered to pregnant women in la-
bor with fetal distress crosses the pla-
centa in a similar way compared with
pregnant women with healthy fetuses
on the brink of delivery.18 Fetal allo-
purinol and/or oxypurinol concentra-
tions, however, were lower in arterial
cord blood in newborns who suffered
from fetal hypoxia compared with
healthy counterparts as reported in
the study by Boda et al.18
Furthermore, we found that, if thera-
peutic allopurinol and/or oxypurinol
concentrations could be established in
the fetus, S-100B concentrations were
substantially lower in arterial cord
blood, suggesting less brain damage
after fetal hypoxia.
However, several questions remain,
which are partly due to the study
set-up and the fact that the number of
patients included in this pilot study
was small. First, it was not possible to
reach therapeutic allopurinol and/or
oxypurinol levels in all neonates. This
may have been because of the brief pe-
riod between treatment and actual
birth of the infant, which prevented op-
timal passage of allopurinol from the
mother to the fetus. This problem is
difﬁcult to solve because the obstetri-
cian will prefer a quick delivery of the
hypoxic fetus. In clinical practice, how-
ever, this problem may be less press-
ing, because additional delay is more
likely to occur in a study set-up be-
cause of the time taken for explanation
of the study and obtaining informed
consent. Moreover, it is possible that a
brief delay of delivery is acceptable if a
clear improvement of the fetal condi-
tion can be veriﬁed by recovery of the
fetal heart rate or fetal scalp blood
samples, gaining some time to achieve
optimal fetal allopurinol concentra-
tions. Another reason for the some-
times subtherapeutic fetal allopurinol
and/or oxypurinol levels may be that
the dosage used in this pilot study,
which was based on placental passage
of (orally administered) allopurinol in
healthy pregnant women in labor,18
was too low because of hindered pla-
cental passage as a result of subopti-
mal placental function or intermittent
umbilical cord occlusion. Given the ab-
sence of any adverse effect of neonatal
or maternal allopurinol treatment in
all human studies performed to
date,9,13,16,18,19 a higher dosage will be
considered in a larger study that is
currently being planned. Although oral
administration may be an option in la-
bor complicated by fetal hypoxia, we
could not detect allopurinol or oxy-
purinol in arterial cord blood of 2 ad-
ditional cases of fetal hypoxia in
which we treated the mother with 600
mg of allopurinol orally (unpublished
observation).
Second, only a short-term chemical
end point with respect to brain dam-
age and neurologic outcome was eval-
uated in the present study: the S-100B
concentration in cord blood. S-100, and
in particular its brain speciﬁc B-
subunit, S-100B in urine and/or blood,
have been reported to be indicators of
cerebral injury,23–24 severity of post–
hypoxic-ischemic encephalopathy,33
and neurodevelopmental outcome34 in
preterm and term infants who suf-
fered from birth asphyxia. A very re-
cent article reports on the relationship
between S-100B in umbilical blood at
birth and acidosis and pathologic
heart rate patterns during labor.25
Moreover, a recent study by Berger et
al35 in infants with traumatic brain in-
jury showed a strong relationship be-
tween S-100B and outcome. However,
long-term follow-up with a detailed as-
sessment of neurodevelopmental out-
come of the children treated antena-
tally with allopurinol or a placebo will
be necessary to prove a neuroprotec-
tive effect of antenatal allopurinol
FIGURE 3
A, Arterial cord concentrations of S-100B (g/L)
of the placebo-treated (vehicle), therapeutic al-
lopurinol and/or oxypurinol (ALLO/OXY), and
subtherapeutic allopurinol and/or oxypurinol
(ALLO/OXY) groups shown as box-whisker
plots. a P  .01 versus placebo and subthera-
peutic allopurinol and/or oxypurinol. B, Sim-
ple linear regression analysis between the
sum of arterial cord concentrations of allo-
purinol and oxypurinol (ALLOOXY) as a func-
tion of S-100B.
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treatment. For this type of study, we
estimate that a total of 200 to 240
cases are needed to assess the effect
of maternal allopurinol treatment on
neurodevelopmental outcome after fe-
tal hypoxia. This rather large number
of inclusions is necessary, because the
outcome of the mature fetus suffering
from fetal hypoxia can be very variable
as shown in earlier studies36–38 and by
the rather normal 5-minute Apgar
scores and umbilical artery pH values
of the 3 groups in the present study.
A ﬁnal comment should be made con-
cerning the free radical marker con-
centrations measured in our study. Al-
though there was an indication that
free radical production was less in the
therapeutic allopurinol and/or oxy-
purinol fetuses, no signiﬁcance was
detected. However, the fact that signif-
icantly fewer cord blood samples had
detectable NPBI in the therapeutic allo-
purinol and/or oxypurinol group may
indicate that allopurinol did reduce
free radical production. Furthermore,
we are also unable to explain the lack
of difference between groups with re-
spect to plasma uric acid in the arte-
rial cord blood. Assuming a substan-
tial inhibition of xanthine oxidase
activity in the therapeutic allopurinol
group, one would expect lower uric
acid concentrations. We postulate that
the time between allopurinol adminis-
tration and measurement of uric acid
concentration may have been too
short to assess differences in between
groups. Furthermore, for xanthine
oxidase to generate uric acid, reperfu-
sion and reoxygenation are required.
This was not the case in the cord
blood that was used for uric acid
determination.
Despite the considerations and uncer-
tainties mentioned above, which may
in part be related to the small sample
size of the present pilot study, the
preliminary results including the sig-
niﬁcantly lower S-100B concentrations
in the therapeutic allopurinol group
make it worthwhile to design a larger
trial. In this trial the most impor-
tant end point should be a clear
marker of long-term neurodevelop-
mental outcome.
CONCLUSIONS
This pilot study shows that allopurinol
crosses the placenta during fetal hyp-
oxia. Given the considerably lower um-
bilical cord allopurinol and oxypurinol
concentrations in the present study
compared with concentrations mea-
sured after oral administration of an
equivalent allopurinol dose tomothers
in uncomplicated labor,18 it is conceiv-
able to assume that a higher allopuri-
nol dosage should be administered
during fetal hypoxia to achieve thera-
peutic concentrations in the hypoxic
fetus. This assumption seems realistic,
because all human studies to date in
which allopurinol was administered to
the mother and fetus or neonate did
not show any short- or long-term ad-
verse effects. Furthermore, newborns
with therapeutic allopurinol and/or
oxypurinol concentrations in cord
blood had lower S-100B concentra-
tions. Therefore, a larger trial in com-
promised fetuses at term seems
warranted.
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